Daelynn Buelow, PhD

Education

• 2002-2007, PhD - University of Alberta: Edmonton, AB, CA
• 2008-2010, Post Doctoral Studies - Washington State University

Publications

• Data from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.c.8031194.
• Figure 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111374.
• Figure 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111371.
• Figure 3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111368.
• Supplementary Figure S1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111365.
• Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111362.
• Supplementary Figure S3 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111359.
• Supplementary Figure S4 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111356.
• Supplementary Figure S5 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111353.
• Supplementary Methods from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111350.
• Table 1 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111347.
• Table 2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, . 2025 Sep | preprint. doi: 10.1158/2767-9764.30111344.
• Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895, Cancer Research Communications. 2025 Sep | journal-article. doi: 10.1158/2767-9764.CRC-25-0265.
• Data from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.c.7926287.
• Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968230.
• Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968227.
• Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968224.
• Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968221.
• Supplementary Methods from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968218.
• Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968215.
• Supplementary Table S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968212.
• Supplementary Table S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968209.
• Supplementary Table S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968206.
• Supplementary Table S5 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968203.
• Supplementary Table S6 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968200.
• Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Aug | preprint. doi: 10.1158/2767-9764.29968197.
• Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557244.
• Figure 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557241.
• Figure 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557238.
• Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557235.
• Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557232.
• Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557229.
• Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557226.
• Supplementary Methods from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557220.
• Supplementary Table S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557217.
• Supplementary Table S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557214.
• Supplementary Table S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557211.
• Supplementary Table S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557208.
• Supplementary Table S5 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557205.
• Supplementary Table S6 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557202.
• Supplementary Table S7 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557193.
• Table 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557190.
• Table 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557187.
• Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, . 2025 Jul | preprint. doi: 10.1158/2767-9764.29557184.
• A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years, Cancer Research Communications. 2025 Jul | journal-article. doi: 10.1158/2767-9764.CRC-25-0091.
• BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors., Blood advances. 2022 Sep | journal-article. doi: 10.1182/bloodadvances.2022007952.
• Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication., Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun | journal-article. doi: 10.1158/1078-0432.ccr-21-4450.
• Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia., Blood advances. 2021 Dec | journal-article. doi: 10.1182/bloodadvances.2021005614.
• Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-Positive AML., Molecular cancer therapeutics. 2021 Sep | journal-article. doi: 10.1158/1535-7163.mct-21-0071.
• DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia., Clinical and translational science. 2020 Sep | journal-article. doi: 10.1111/cts.12861.
• Skin fibroblasts of patients with geleophysic dysplasia due to FBN1 mutations have lysosomal inclusions and losartan improves their microfibril deposition defect., Molecular genetics & genomic medicine. 2019 Jul | journal-article. doi: 10.1002/mgg3.844.
• Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML., Investigational new drugs. 2019 May | journal-article. doi: 10.1007/s10637-019-00786-4.
• A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML., Nature communications. 2019 May | journal-article. doi: 10.1038/s41467-019-09917-0.
• Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms., Nature communications. 2019 Jan | journal-article. doi: 10.1038/s41467-018-08263-x.
• Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia., The Journal of clinical investigation. 2017 Dec | journal-article. doi: 10.1172/jci91893.
• Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation., Leukemia & lymphoma. 2016 Jun | journal-article. doi: 10.1080/10428194.2016.1187272.
• Comparative Evaluation of Four Real-Time PCR Methods for the Quantitative Detection of Epstein-Barr Virus from Whole Blood Specimens., The Journal of molecular diagnostics : JMD. 2016 May | journal-article. doi: 10.1016/j.jmoldx.2016.02.002.
• Quantitative Assessment of Commutability for Clinical Viral Load Testing Using a Digital PCR-Based Reference Standard., Journal of clinical microbiology. 2016 Apr | journal-article. doi: 10.1128/jcm.03346-15.
• ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression., Clinical and translational science. 2016 Feb | journal-article. doi: 10.1111/cts.12366.
• Quantitative multiplexed detection of common pulmonary fungal pathogens by labeled primer polymerase chain reaction., Archives of pathology & laboratory medicine. 2014 Nov | journal-article. doi: 10.5858/arpa.2013-0592-oa.
• Comparison of two multiplexed PCR assays for the detection of HSV-1, HSV-2, and VZV with extracted and unextracted cutaneous and mucosal specimens., Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2013 Jun | journal-article. doi: 10.1016/j.jcv.2013.05.008.
• Capsaicin-sensitive vagal afferent neurons contribute to the detection of pathogenic bacterial colonization in the gut., Journal of neuroimmunology. 2013 Mar | journal-article. doi: 10.1016/j.jneuroim.2013.01.009.
• PCR followed by electrospray ionization mass spectrometry for broad-range identification of fungal pathogens., Journal of clinical microbiology. 2013 Jan | journal-article. doi: 10.1128/jcm.02621-12.
• Evaluation of multiplexed PCR and liquid-phase array for identification of respiratory fungal pathogens., Medical mycology. 2012 Mar | journal-article. doi: 10.3109/13693786.2012.666681.
• Campylobacter jejuni survival within human epithelial cells is enhanced by the secreted protein CiaI., Molecular microbiology. 2011 Apr | journal-article. doi: 10.1111/j.1365-2958.2011.07645.x.
• Structure of the periplasmic stress response protein CpxP., Journal of bacteriology. 2011 Feb | journal-article. doi: 10.1128/jb.01296-10.
• Three (and more) component regulatory systems - auxiliary regulators of bacterial histidine kinases., Molecular microbiology. 2009 Nov | journal-article. doi: 10.1111/j.1365-2958.2009.06982.x.
• Two-component signaling and gram negative envelope stress response systems., Advances in experimental medicine and biology. 2008 Jan | journal-article. doi: 10.1007/978-0-387-78885-2_6.
• Cpx signal transduction is influenced by a conserved N-terminal domain in the novel inhibitor CpxP and the periplasmic protease DegP., Journal of bacteriology. 2005 Oct | journal-article. doi: 10.1128/jb.187.19.6622-6630.2005.